Lenalidomide Capsule
Product Images NDC 0378-1937

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 0378-1937). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lenalidomide Capsules 5 mg Bottle Label (Image 02)

Lenalidomide Capsules 5 mg oral dosage form label from Mylan Pharmaceuticals Inc. The label includes dosage strength, NDC 0378-1936-28, warnings about potential birth defects, pharmacy instructions, storage conditions, and container requirements. The package contains 28 capsules and features barcodes and variable data coding areas.*

FDA Label Image

Lenalidomide Capsules 10 mg Bottle Label (Image 03)

Lenalidomide 10 mg capsules packaging label by Mylan Pharmaceuticals Inc. The label displays the product name, strength, dosage form, and a warning about potential birth defects. It includes storage instructions, manufacturer information, a barcode, and indicates the package contains 28 capsules for oral use.*

FDA Label Image

Lenalidomide Capsules 15 mg Bottle Label (Image 04)

Label for Lenalidomide capsules 15 mg by Mylan Pharmaceuticals Inc. The label includes dosage and storage instructions, a warning about human birth defects, and dispensing information. It states the package contains 21 capsules and emphasizes safe handling and child-resistant packaging. The label shows barcodes and a sample area for lot and expiration data.*

FDA Label Image

Lenalidomide Capsules 25 mg Bottle Label (Image 06)

Lenalidomide 25 mg capsules label from Mylan Pharmaceuticals Inc. The label includes the proprietary and generic name, strength (25 mg), quantity (21 capsules), a warning about potential human birth defects, dosing advisory, storage instructions, and a barcode. The capsules are manufactured in India and packaged for oral use.*

FDA Label Image

Lenalidomide Structural Formula (Image 07)

Chemical structure of lenalidomide, showing its molecular arrangement including an amino group, isoindolinone, and piperidine-2,6-dione rings as labeled. The structure is drawn with bonds representing the chemical connectivity.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival Based On Irac Assessment (itt Mm Population) Between Arms Rd Continuous, Rd18 And Mpt Cutoff Date: 24 May 2013 (Image 08)

A line graph depicting progression-free survival over months for Lenalidomide regimens. The x-axis shows time in months, while the y-axis shows survival probability percentage. Three treatment groups (Rd Continuous, Rd18, MPT) are compared, with Rd Continuous showing the highest survival probability over time. A table below the graph lists the number of subjects at risk at various time points for each group. The graph includes hazard ratios and statistical significance values.*

FDA Label Image

Kaplan-meier Curves Of Overall Survival (itt Mm Population) Between Arms Rd Continuous, Rd18 And Mpt Cutoff Date: 03 Mar 2014 (Image 09)

A Kaplan-Meier survival curve chart showing overall survival probability (%) over time in months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart includes hazard ratios with 95% confidence intervals comparing these groups. The number of subjects at risk at various time points is displayed below the x-axis, and explanatory abbreviations for terms used in the chart are provided.*

FDA Label Image

Kaplan-meier Estimate Of Time To Progression — Mm Study 1 (Image 10)

A Kaplan-Meier survival curve chart showing time to progression (months) on the x-axis and proportion of subjects on the y-axis. The chart compares Lenalidomide/Dex treatment versus Placebo/Dex, illustrating a higher proportion of subjects without progression over time in the Lenalidomide/Dex group. Statistical values including hazard ratio (HR 0.285 with 95% CI 0.210-0.386) and a significant Log Rank p-value (< 0.001) are displayed on the graph.*

FDA Label Image

Kaplan-meier Estimate Of Time To Progression — Mm Study 2 (Image 11)

A Kaplan-Meier progression-free survival curve comparing Lenalidomide/Dex treatment to Placebo/Dex over time, measured in months. The graph shows proportion of subjects on the y-axis and time to progression on the x-axis, with Lenalidomide/Dex demonstrating a higher proportion of subjects without progression over time. Statistical data including hazard ratio (HR 0.324, 95% CI 0.240-0.438) and log-rank p-value (<0.001) are included.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-auto-hsct Population) In Mm Maintenance Study 1 Between Lenalidomide Capsules And Placebo Arms (updated Cutoff Date 1 March 2015) (Image 12)

A Kaplan-Meier survival curve comparing progression-free survival in months between Lenalidomide and placebo groups. The chart shows higher survival probability for Lenalidomide over time. Below the graph, a table lists the number of subjects at risk at various time points for each group. Event percentages for progression-free survival are also noted.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival From Randomization (itt Post-auto-hsct Population) In Mm Maintenance Study 2 Between Lenalidomide Capsules And Placebo Arms (updated Cutoff Date 1 March 2015) (Image 13)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months for Lenalidomide versus placebo. The chart displays two lines, indicating higher survival probability for Lenalidomide compared to placebo across the study period, with number of subjects at risk listed below the x-axis and progression-free survival events noted.*

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival By Irc Assessment Between Arms In Augment Trial (itt Fl And Mzl Population) (Image 14)

A Kaplan-Meier survival curve graph showing progression-free survival probability over months comparing two groups: Rituximab + Lenalidomide and Rituximab + Placebo. The graph plots survival probability on the y-axis and progression-free survival in months on the x-axis, with a risk table below indicating the number of subjects at risk over time. Statistical values including hazard ratio (HR) and log-rank p-value are displayed on the chart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.